ANRO Alto Neuroscience, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1999480 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-52.9%
TTM EPS YoY-0.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-46.6%
ROA-40.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets9.2%
Debt / equity0.05x
Current ratio18.12x
Interest coverage-48.48x
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $18.16M | $22.11M | $20.29M | $12.00M | $10.53M | $13.12M | $9.97M | $10.80M |
| SG&A expense | $9.06M | $7.02M | $6.84M | $5.06M | $4.43M | $5.56M | $5.70M | $6.20M |
| Operating income | -$27.23M | -$29.13M | -$27.14M | -$17.05M | -$14.95M | -$18.68M | -$15.68M | -$17.00M |
| Interest expense | $463,000 | $491,000 | $545,000 | $575,000 | $650,000 | $646,000 | $598,000 | $333,000 |
| Income tax | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Net income | -$25.12M | -$27.64M | -$26.24M | -$16.18M | -$14.18M | -$17.71M | -$15.17M | -$15.20M |
| EBITDA | -$27.12M | -$28.93M | -$26.95M | -$16.90M | -$14.75M | -$18.58M | -$15.51M | -$16.83M |
| EPS (basic) | -0.54 | -0.65 | -0.80 | — | -0.52 | -0.65 | -0.56 | — |
| EPS (diluted) | -0.54 | -0.65 | -0.80 | — | -0.52 | -0.65 | -0.56 | — |
| Weighted avg. shares (diluted) | 46.53M | 42.81M | 32.89M | — | 27.10M | 27.07M | 27.05M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $319.34M | $243.73M | $263.76M | $176.48M | $138.32M | $148.09M | $161.25M | $168.73M |
| Current assets | $323.20M | $247.32M | $269.13M | $177.72M | $139.45M | $149.85M | $163.52M | $169.34M |
| PP&E, net | $1.87M | $2.05M | $2.23M | $1.87M | $2.03M | $2.31M | $2.48M | $2.67M |
| Total assets | $326.50M | $254.07M | $276.26M | $184.69M | $147.01M | $157.88M | $171.91M | $177.54M |
| Current liabilities | $17.84M | $16.65M | $13.12M | $11.32M | $9.04M | $8.13M | $7.26M | $10.01M |
| Short-term debt | $4.51M | $3.77M | $2.14M | $585,000 | — | — | — | $0 |
| Long-term debt | $8.97M | $12.42M | $13.88M | $16.17M | $20.31M | $20.12M | $19.94M | $10.25M |
| Total debt | $13.48M | $16.19M | $16.02M | $16.76M | $20.31M | $20.12M | $19.94M | $10.25M |
| Total liabilities | $29.98M | $34.82M | $32.89M | $33.55M | $35.45M | $34.47M | $32.82M | $26.08M |
| Shareholders' equity | $296.53M | $219.25M | $243.37M | $151.14M | $111.56M | $123.41M | $139.10M | $151.46M |
| Net debt | -$305.86M | -$227.55M | -$247.74M | -$159.73M | -$118.00M | -$127.96M | -$141.31M | -$158.47M |
| Shares outstanding | 39.98M | 35.09M | 35.05M | 31.92M | 27.17M | 27.07M | 27.07M | 26.99M |
| Cash flow statement | ||||||||
| Operating cash flow | -$20.76M | -$19.76M | -$27.09M | -$11.52M | -$9.92M | -$13.78M | -$16.56M | -$13.02M |
| Capital expenditure | $0 | $0 | $556,000 | $0 | $0 | $0 | $24,000 | $506,000 |
| Free cash flow | -$20.76M | -$19.76M | -$27.65M | -$11.52M | -$9.92M | -$13.78M | -$16.58M | -$13.53M |
| Investing cash flow | $0 | $0 | -$556,000 | $0 | $0 | $0 | -$24,000 | -$506,000 |
| Financing cash flow | $96.36M | -$273,000 | $114.94M | $50.19M | $153,000 | $613,000 | $9.13M | $49,000 |
| Depreciation & amortization | $100,000 | $200,000 | $184,000 | $157,000 | $200,000 | $100,000 | $171,000 | $170,000 |
| Stock-based compensation | $3.52M | $3.55M | $2.82M | $1.95M | $2.19M | $2.00M | $1.97M | $1.57M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.